How to buy Akorn stock

Akorn, Inc is a drug manufacturers—specialty & generic business based in the US. Akorn shares (AKRX) are listed on the NASDAQ and all prices are listed in US Dollars. Akorn employs 2,227 staff and has a trailing 12-month revenue of around USD$721.3 million.

How to buy shares in Akorn

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Akorn. Find the stock by name or ticker symbol: AKRX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Akorn reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Akorn, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Akorn. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Akorn share price

Use our graph to track the performance of AKRX stocks over time.

Akorn shares at a glance

• Key figures

Information last updated 2020-10-22.

52-week range	USD$0.0121 - USD$4.18
50-day moving average	USD$0.0379
200-day moving average	USD$0.181
Wall St. target price	USD$2
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-3.818

Buy Akorn shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Akorn stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Akorn, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Akorn under- or over-valued?

Valuing Akorn stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Akorn's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Akorn's EBITDA

Akorn's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$46.9 million.

The EBITDA is a measure of a Akorn's overall financial performance and is widely used to measure a its profitability.

Akorn financials

Revenue TTM	USD$721.3 million
Gross profit TTM	USD$252.7 million
Return on assets TTM	-0.94%
Return on equity TTM	-231.8%
Profit margin	-55.64%
Book value	$1.857
Market capitalisation	USD$12 million

TTM: trailing 12 months

Shorting Akorn shares

There are currently 11.9 million Akorn shares held short by investors – that's known as Akorn's "short interest". This figure is 10.9% up from 10.8 million last month.

There are a few different ways that this level of interest in shorting Akorn shares can be evaluated.

Akorn's "short interest ratio" (SIR)

Akorn's "short interest ratio" (SIR) is the quantity of Akorn shares currently shorted divided by the average quantity of Akorn shares traded daily (recently around 24.3 million). Akorn's SIR currently stands at 0.49. In other words for every 100,000 Akorn shares traded daily on the market, roughly 490 shares are currently held short.

However Akorn's short interest can also be evaluated against the total number of Akorn shares, or, against the total number of tradable Akorn shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Akorn's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Akorn shares in existence, roughly 90 shares are currently held short) or 0.1029% of the tradable shares (for every 100,000 tradable Akorn shares, roughly 103 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Akorn.

Find out more about how you can short Akorn stock.

Akorn share dividends

We're not expecting Akorn to pay a dividend over the next 12 months.

Akorn share price volatility

Over the last 12 months, Akorn's shares have ranged in value from as little as $0.0121 up to $4.18. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akorn's is 1.1428. This would suggest that Akorn's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Akorn overview

Akorn, Inc., a specialty pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Further, the company sells its products to wholesale distributors. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois. On May 20, 2020, Akorn, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Frequently asked questions

• What percentage of Akorn is owned by insiders or institutions?

  Currently 8.143% of Akorn shares are held by insiders and 75.927% by institutions.

• How many people work for Akorn?

  Latest data suggests 2,227 work at Akorn.

• When does the fiscal year end for Akorn?

  Akorn's fiscal year ends in December.

• Where is Akorn based?

  Akorn's address is: 1925 West Field Court, Lake Forest, IL, United States, 60045

• What is Akorn's ISIN number?

  Akorn's international securities identification number is: US0097281069

• What is Akorn's CUSIP number?

  Akorn's Committee on Uniform Securities Identification Procedures number is: 009728106